The Priority Review

Tag

rilzabrutinib

1 story

  1. Clinical trials

    Sanofi registers Phase 2 and 3 study of rilzabrutinib in iCVID

    The study, first posted on ClinicalTrials.gov on November 6, 2026, plans to enroll 96 participants and has a planned start date of November 9, 2026. It evaluates efficacy, safety, and tolerability of rilzabrutinib in adults with inflammatory common variable immunodeficiency over four parts, with a planned primary completion date of May 10, 2035.